by Instem Team | Mar 12, 2026 | Clinical
Across the life sciences sector, pressure on R&D productivity and profitability is intensifying. Pricing constraints, patent expirations, and organizational restructuring are forcing pharmaceutical and biotech companies to do more with fewer resources. At the same...
by Instem Team | Mar 11, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Discovery Given that a single high-throughput screening campaign may evaluate over 2 million compounds, discovery teams must move through terabytes of data before deciding to prioritize only a handful of compounds after target identification. When data and rationale...
by Instem Team | Mar 6, 2026 | Clinical, Resources
Open-source software has been increasingly popular in biostatistics and life sciences. While SAS has been the go-to programming language for biostatistics, R and other open-source languages are being utilized more often. R, known for its distinct capabilities and...
by Instem Team | Mar 4, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
The earliest stages of drug research and development (R&D) generate massive volumes of scientific, operational, and compliance-critical data, often across disconnected tools, teams, and formats. That fragmentation slows decision-making, increases rework, and...
by Instem Team | Mar 3, 2026 | Company News
Instem is pleased to announce the completion of a significant refurbishment of its Stone, UK Headquarters. The revitalisation of the UK Headquarters is a strategic investment reflecting Instem’s commitment to excellence, innovation, and the creation of a modern...
